Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREMENDOUS: Durvalumab and Tremelimumab as First-Line Treatment in Unresectable Hepatocellular Carcinoma
NCT05557838Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: >=Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1 up to 44 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05557838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557838.